CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
26 05 2020
Historique:
received: 25 10 2019
revised: 28 02 2020
accepted: 04 05 2020
entrez: 28 5 2020
pubmed: 28 5 2020
medline: 22 5 2021
Statut: ppublish

Résumé

Acute myeloid leukemia (AML) is defined by an accumulation of immature myeloid blasts in the bone marrow. To identify key dependencies of AML stem cells in vivo, here we use a CRISPR-Cas9 screen targeting cell surface genes in a syngeneic MLL-AF9 AML mouse model and show that CXCR4 is a top cell surface regulator of AML cell growth and survival. Deletion of Cxcr4 in AML cells eradicates leukemia cells in vivo without impairing their homing to the bone marrow. In contrast, the CXCR4 ligand CXCL12 is dispensable for leukemia development in recipient mice. Moreover, expression of mutated Cxcr4 variants reveals that CXCR4 signaling is essential for leukemia cells. Notably, loss of CXCR4 signaling in leukemia cells leads to oxidative stress and differentiation in vivo. Taken together, our results identify CXCR4 signaling as essential for AML stem cells by protecting them from differentiation independent of CXCL12 stimulation.

Identifiants

pubmed: 32460032
pii: S2211-1247(20)30637-9
doi: 10.1016/j.celrep.2020.107684
pmc: PMC8109054
mid: NIHMS1693424
pii:
doi:

Substances chimiques

CXCL12 protein, human 0
CXCR4 protein, human 0
Chemokine CXCL12 0
MLL-AF9 fusion protein, mouse 0
Oncogene Proteins, Fusion 0
Reactive Oxygen Species 0
Receptors, CXCR4 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107684

Subventions

Organisme : NCI NIH HHS
ID : R01 CA172447
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA248794
Pays : United States

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare no competing interests.

Références

Blood Adv. 2017 Oct 18;1(23):2046-2057
pubmed: 29296851
Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):9928-33
pubmed: 27543332
Sci Rep. 2016 Nov 25;6:37827
pubmed: 27886253
Cancer Discov. 2016 Aug;6(8):914-29
pubmed: 27260156
J Mol Med (Berl). 2014 May;92(5):433-9
pubmed: 24722947
Cancer Cell. 2013 Oct 14;24(4):423-37
pubmed: 24054986
Cell Rep. 2018 Jan 9;22(2):350-358
pubmed: 29320732
Leukemia. 2000 Oct;14(10):1777-84
pubmed: 11021753
J Biol Chem. 2003 Jan 31;278(5):3378-85
pubmed: 12433920
J Exp Med. 2008 Apr 14;205(4):777-83
pubmed: 18378795
Cell Death Differ. 2006 May;13(5):785-97
pubmed: 16528384
Biochem Biophys Res Commun. 2010 Feb 19;392(4):495-9
pubmed: 20093106
Stem Cells. 2004;22(2):188-201
pubmed: 14990858
Nat Med. 2006 Oct;12(10):1167-74
pubmed: 16998484
Cell Stem Cell. 2015 Mar 5;16(3):254-67
pubmed: 25748932
Cell. 2016 Apr 7;165(2):303-16
pubmed: 27058663
Blood. 2007 Jan 15;109(2):786-91
pubmed: 16888090
Blood. 2011 Jan 13;117(2):429-39
pubmed: 20833981
J Virol. 2005 Dec;79(24):15398-404
pubmed: 16306611
Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16280-5
pubmed: 20805474
Leukemia. 2018 Mar;32(3):588-596
pubmed: 28819278
Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10786-91
pubmed: 26261316
Nature. 2017 Jul 6;547(7661):104-108
pubmed: 28658204
Nat Rev Genet. 2015 Jan;16(1):18-32
pubmed: 25446316
Nat Genet. 2017 Jun;49(6):866-875
pubmed: 28436985
Nature. 2013 Mar 14;495(7440):231-5
pubmed: 23434755
Cancer Cell. 2015 Jun 8;27(6):769-79
pubmed: 26058076
Haematologica. 2019 Oct;104(10):2006-2016
pubmed: 30819903
Nat Med. 2007 May;13(5):587-96
pubmed: 17435771
Nat Med. 1999 Jun;5(6):669-76
pubmed: 10371506
Blood. 2006 Mar 15;107(6):2243-51
pubmed: 16291599
Blood. 2015 Apr 16;125(16):2544-52
pubmed: 25740828
Nature. 2019 Apr;568(7753):511-516
pubmed: 30971826
Nat Biotechnol. 2014 Sep;32(9):941-6
pubmed: 24952903
Nature. 2019 Apr;568(7753):551-556
pubmed: 30971823
Leukemia. 2008 Dec;22(12):2151-5158
pubmed: 18769446
Leuk Res. 2007 Nov;31(11):1553-63
pubmed: 17403536
Nature. 2013 Mar 14;495(7440):227-30
pubmed: 23434756
Cancer Cell. 2013 Jul 8;24(1):45-58
pubmed: 23770013
N Engl J Med. 2013 May 30;368(22):2059-74
pubmed: 23634996
Cell Stem Cell. 2009 Jul 2;5(1):31-42
pubmed: 19570512
Leukemia. 2017 Nov;31(11):2336-2346
pubmed: 28280274
Nature. 2011 Aug 03;478(7370):524-8
pubmed: 21814200
Nature. 1998 Jun 11;393(6685):595-9
pubmed: 9634238
J Exp Med. 2014 Apr 7;211(4):605-12
pubmed: 24616378
Sci Transl Med. 2017 Jan 25;9(374):
pubmed: 28123069
Nat Med. 2006 Apr;12(4):446-51
pubmed: 16565722
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
PLoS One. 2017 Sep 25;12(9):e0185354
pubmed: 28945785
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Appl Immunohistochem Mol Morphol. 2013 Jan;21(1):79-84
pubmed: 22914607
Nature. 2006 Aug 17;442(7104):818-22
pubmed: 16862118
Blood Adv. 2017 Jun 21;1(15):1088-1100
pubmed: 29296751
J Biol Chem. 2010 May 14;285(20):15566-15576
pubmed: 20228059
Science. 2010 Mar 26;327(5973):1650-3
pubmed: 20339075
Cancer Med. 2019 Nov;8(15):6595-6603
pubmed: 31518054
Cell Stem Cell. 2019 May 2;24(5):769-784.e6
pubmed: 30905620
Blood. 2009 Mar 12;113(11):2375-85
pubmed: 19056693
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
Cancer Discov. 2016 Aug;6(8):900-13
pubmed: 27260157
J Exp Med. 2019 Oct 7;216(10):2362-2377
pubmed: 31371381
Nature. 2016 Apr 21;532(7599):323-8
pubmed: 27074509
Cell. 2009 Jul 23;138(2):286-99
pubmed: 19632179
Haematologica. 2017 Apr;102(4):707-718
pubmed: 28126968
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Ann N Y Acad Sci. 2005 Jun;1044:1-5
pubmed: 15958691
Cancer Cell. 2015 May 11;27(5):671-81
pubmed: 25965572
Blood. 1998 Jun 15;91(12):4523-30
pubmed: 9616148
Exp Hematol. 2016 Jul;44(7):540-60
pubmed: 27179622
Nat Chem Biol. 2013 Dec;9(12):840-848
pubmed: 24161946
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11103-8
pubmed: 23690610
Cancer Res. 2004 Apr 15;64(8):2817-24
pubmed: 15087398
Immunity. 2006 Dec;25(6):977-88
pubmed: 17174120

Auteurs

Ramprasad Ramakrishnan (R)

Division of Clinical Genetics, Lund University, Lund 22184, Sweden.

Pablo Peña-Martínez (P)

Division of Clinical Genetics, Lund University, Lund 22184, Sweden.

Puneet Agarwal (P)

Division of Hematology & Oncology, University of Alabama Birmingham, Birmingham, AL 35233, USA.

Maria Rodriguez-Zabala (M)

Division of Clinical Genetics, Lund University, Lund 22184, Sweden.

Marion Chapellier (M)

Division of Clinical Genetics, Lund University, Lund 22184, Sweden.

Carl Högberg (C)

Division of Clinical Genetics, Lund University, Lund 22184, Sweden.

Mia Eriksson (M)

Division of Clinical Genetics, Lund University, Lund 22184, Sweden.

David Yudovich (D)

Division of Molecular Medicine and Gene Therapy, Lund University, Lund 22184, Sweden.

Mansi Shah (M)

Division of Hematology & Oncology, University of Alabama Birmingham, Birmingham, AL 35233, USA.

Mats Ehinger (M)

Division of Pathology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund 22184, Sweden.

Björn Nilsson (B)

Division of Hematology and Transfusion Medicine, Lund University, Lund 22184, Sweden.

Jonas Larsson (J)

Division of Molecular Medicine and Gene Therapy, Lund University, Lund 22184, Sweden.

Anna Hagström-Andersson (A)

Division of Clinical Genetics, Lund University, Lund 22184, Sweden.

Benjamin L Ebert (BL)

Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA.

Ravi Bhatia (R)

Division of Hematology & Oncology, University of Alabama Birmingham, Birmingham, AL 35233, USA.

Marcus Järås (M)

Division of Clinical Genetics, Lund University, Lund 22184, Sweden. Electronic address: marcus.jaras@med.lu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH